share_log

凯普生物(300639.SZ): 全资子公司磷酸氯喹凝胶获得药物临床试验批准通知书

Guangdong Hybribio Biotech (300639.SZ): The wholly-owned subsidiary, Chloroquine Phosphate Gel, has obtained the Notice of Approval for Clinical Trials of Medicines.

Gelonghui Finance ·  Sep 20, 2024 20:10

Gelonghui September 20th | Guangdong Hybribio Biotech (300639.SZ) announced that recently, its wholly-owned subsidiary Guangzhou Guangdong Hybribio Technology Co., Ltd. has received the drug clinical trial approval notice for "Chloroquine Phosphate Gel" issued by the National Medical Products Administration, allowing the product to conduct clinical trials for high-risk HPV virus infections.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment